Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same-arm versus opposite-arm coadministration of COVID-19 and influenza vaccines
ACTRN12624000445572Phase 2Active, not recruiting
- Sponsor
- University of Melbourne
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran and Influenza A (H1N1) vaccine in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by University of Melbourne. Primary endpoint: Fold difference in combined post-vaccination HAI titre to 3 influenza vaccine strains. Started Mar 2024; status: active, not recruiting.
02
Drugs
elasomeranInfluenza A (H1N1) vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on ACTRN12624000445572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000445572.